Production (Stage)
Plus Therapeutics, Inc.
PSTV
$0.3358
-$0.0239-6.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -25.00% | -3.02% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -25.00% | -3.02% | |||
| Cost of Revenue | -19.67% | -23.51% | |||
| Gross Profit | 9.95% | 44.79% | |||
| SG&A Expenses | -9.18% | 30.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.50% | 1.08% | |||
| Operating Income | 9.33% | -2.66% | |||
| Income Before Tax | -345.84% | -35.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -345.84% | -35.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -345.84% | -35.80% | |||
| EBIT | 9.33% | -2.66% | |||
| EBITDA | 8.40% | -2.81% | |||
| EPS Basic | -140.70% | -35.68% | |||
| Normalized Basic EPS | -140.68% | -35.64% | |||
| EPS Diluted | -140.70% | -34.14% | |||
| Normalized Diluted EPS | -140.68% | -35.64% | |||
| Average Basic Shares Outstanding | 85.22% | 0.11% | |||
| Average Diluted Shares Outstanding | 85.22% | 0.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||